X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Hangzhou Company will acquire I-Mab drug assets in China, including the Greater China rights for TJ101 (eftansomatropin alfa), MOR202 (felzartamab), uliledlimab, givastomig, and lemzoparlimab.
Lead Product(s): Eftansomatropin Alfa
Therapeutic Area: Endocrinology Product Name: TJ101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: I-Mab Hangzhou Company
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Divestment February 07, 2024
Details:
MOR202 (felzartamab) is human monoclonal antibody directed against CD38, a protein expressed on mature plasma cells. In PMN, CD38+long-lived plasma cells drive pathogenic antibody production, contributing to functional damage to the glomeruli in the kidney.
Lead Product(s): Felzartamab
Therapeutic Area: Nephrology Product Name: MOR202
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
TJ-L14B/ABL503, is a differentiated PD-L1 x 4-1BB bispecific antibody, which is investigated in patients with progressive, locally advanced or metastatic solid tumors who are relapsed or refractory following prior lines of treatment.
Lead Product(s): TJ-L14B
Therapeutic Area: Oncology Product Name: ABL503
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ABL Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
Under the termination, I-Mab will regain the full global rights to develop and commercialize certain CD47 compounds and products under the Collaboration Agreement, including TJC4 (lemzoparlimab), a fully human anti-CD47 IgG4 antibody.
Lead Product(s): Lemzoparlimab,Azacitidine
Therapeutic Area: Oncology Product Name: TJC4
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $1,940.0 million Upfront Cash: $180.0 million
Deal Type: Termination September 22, 2023
Details:
Genexine’s, GX-H9, a proprietary long-acting growth hormone shows positive topline results from phase 3 study for growth hormone deficiency, is being conducted in China with I-Mab.
Lead Product(s): Eftansomatropin Alfa
Therapeutic Area: Endocrinology Product Name: GX-H9
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Genexine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
ABBV-IMAB-TJC4 (lemzoparlimab) is a novel CD47 antibody, in combination with azacitidine (AZA), currently being investigated in China for patients with higher-risk myelodysplastic syndrome (MDS).
Lead Product(s): Lemzoparlimab,Azacitidine
Therapeutic Area: Oncology Product Name: ABBV-IMAB-TJC4
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
Data showed an increased calreticulin (CALR) expression in CD33+ blasts after lemzoparlimab and AZA combination treatment and higher immune infiltrates including total, CD91+ macrophages and CD8/Treg ratio in bone marrow at baseline is associated with better clinical response.
Lead Product(s): Lemzoparlimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: ABBV-IMAB-TJC4
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Uliledlimab (also known as TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.
Lead Product(s): Uliledlimab,Atezolizumab
Therapeutic Area: Oncology Product Name: TJD5
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Top-line efficacy data demonstrated that lemzoparlimab (TJ011133) combined with azacitidine showed encouraging clinical response in HR-MDS patients. Results also showed that lemzoparlimab combined with Azacitidine can be safely administered without the need of a priming dose.
Lead Product(s): Lemzoparlimab,Azacitidine
Therapeutic Area: Oncology Product Name: TJ011133
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Lemzoparlimab (TJ011133) combined with AZA showed encouraging clinical response in higher-risk MDS patients For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40%.
Lead Product(s): Lemzoparlimab,Azacitidine
Therapeutic Area: Oncology Product Name: TJ011133
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
